PMID: 7016302Jul 15, 1981Paper

Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum

Cancer
E Y HilalH F Oettgen

Abstract

The authors' previous surgical adjuvant trial in patients with malignant melanoma at high risk of recurrence has shown no difference in disease-free interval or survival between patients randomized to surgery + BCG or surgery alone. Reported here is a subsequent nonrandomized trial in 30 similar patients who received surgery + Corynebacterium parvum (CP) 4 mg I.V. daily x 5, followed by 4 mg S.C. weekly for up to three years. After I.V. C. parvum, chills, fever, headache, and hypertension were common. After S.C. C. parvum, varying degrees of local induration, erythema, and pain were experienced. Dose reduction was necessary for 14 patients during I.V. treatment and for six patients during S.C. treatment. A marked decrease in absolute lymphocyte count and a decreased proliferative response of lymphocytes to common antigens in vitro was observed after 2-3 days of I.V. C. parvum. Lymphocyte reactivity to mitogens decreased, particularly with Con A. Marked increase in nitroblue tetrazolium reduction by granulocytes was seen in 20 patients. Although changes in delayed cutaneous hypersensitivity reactions to recall antigens followed no consistent pattern, reactivity to DNCB increased in 18 patients. In addition, median time to recurr...Continue Reading

References

Apr 26, 1975·Lancet·L Israel, R Edelstein
Jan 29, 1976·The New England Journal of Medicine·F R EilberK P Ramming
May 1, 1976·The Medical Clinics of North America·H F OettgenL Delmonte
Sep 1, 1974·Journal of the National Cancer Institute·M T Scott
Nov 15, 1974·International Journal of Cancer. Journal International Du Cancer·V V Likhite
Feb 1, 1974·Journal of the National Cancer Institute·D PaslinC Heaton

❮ Previous
Next ❯

Citations

Sep 1, 1987·Journal of Surgical Oncology·C P Karakousis, L J Emrich
Jan 1, 1985·Medical and Pediatric Oncology·H K KohR W Carey
May 30, 2003·Seminars in Cutaneous Medicine and Surgery·Larisa GeskinJohn M Kirkwood
Jul 1, 1992·The Journal of Dermatologic Surgery and Oncology·D P Tahery, R L Moy
Aug 1, 1984·The Australian and New Zealand Journal of Surgery·P Hersey, C M Balch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.